List view / Grid view
12 December 2014 | By Roche
At its December meeting, the Board of Directors (BoD) of Roche Holding recommended first proposals for approval by the AGM, scheduled for 3 March 2015...
10 December 2014 | By Roche
New data demonstrate high prognostic value of Elecsys blood test...
9 December 2014 | By Roche
Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting...
9 December 2014 | By Roche
Presentations include data on Roche’s broad portfolio of hematology medicines as well as emerging investigational agents including ACE910 (RG6013) in hemophilia A...
9 December 2014 | By Roche
Victory for Scottish NHS patients as SMC accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia...
9 December 2014 | By Roche
cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems...
2 December 2014 | By Roche
Victory for patients as NICE accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia1...
2 December 2014 | By Roche
Roche announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa), a privately-held company based in San Jose, California, USA...
25 November 2014 | By Roche
Roche is increasing the payroll for its workforce of over 13,000 in Switzerland by 1.4 percent with effect from 1 April 2015...
17 November 2014 | By Roche
Avastin plus chemotherapy reduced the risk of the disease worsening by 62 percent compared to chemotherapy alone in a Phase III study...
14 November 2014 | By Roche
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection...
5 November 2014 | By Roche
Addressing Asia Pacific’s growing demand for diagnostics...
27 October 2014 | By Roche
Roche announced that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, strengthening the efficacy claims and supporting the well-established safety profile based on the additional data from the phase III ASCEND trial...
22 October 2014 | By Roche
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development...
16 October 2014 | By Roche
Roche announce Q3 2014 results...
